GSK is abandoning one of its new drug prospects after it failed in hard-to-treat rheumatoid arthritis patients at Phase III, raising the stakes for more key readouts due shortly.

The Indian clinical research segment has managed to retain some buoyancy despite pandemic-related disruptions, with an estimated 70 global trials cleared to October by the regulator. But audiovisual recording of the informed consent process has been particularly challenging in the case of subjects in isolation wards.